nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—UGT1A9—Mycophenolic acid—systemic scleroderma	0.289	0.353	CbGbCtD
Ezogabine—UGT1A1—Mycophenolic acid—systemic scleroderma	0.236	0.289	CbGbCtD
Ezogabine—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.162	0.197	CbGbCtD
Ezogabine—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.132	0.161	CbGbCtD
Ezogabine—Malnutrition—Leflunomide—systemic scleroderma	0.000541	0.00299	CcSEcCtD
Ezogabine—Confusional state—Captopril—systemic scleroderma	0.00054	0.00299	CcSEcCtD
Ezogabine—Dyspepsia—Mometasone—systemic scleroderma	0.000537	0.00297	CcSEcCtD
Ezogabine—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.000532	0.00294	CcSEcCtD
Ezogabine—Ill-defined disorder—Azathioprine—systemic scleroderma	0.000532	0.00294	CcSEcCtD
Ezogabine—Hallucination—Lisinopril—systemic scleroderma	0.000532	0.00294	CcSEcCtD
Ezogabine—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000528	0.00292	CcSEcCtD
Ezogabine—Shock—Captopril—systemic scleroderma	0.000527	0.00292	CcSEcCtD
Ezogabine—Oedema peripheral—Lisinopril—systemic scleroderma	0.000526	0.00291	CcSEcCtD
Ezogabine—Fatigue—Mometasone—systemic scleroderma	0.000526	0.00291	CcSEcCtD
Ezogabine—Thrombocytopenia—Captopril—systemic scleroderma	0.000525	0.0029	CcSEcCtD
Ezogabine—Alopecia—Mycophenolic acid—systemic scleroderma	0.000524	0.0029	CcSEcCtD
Ezogabine—Urethral disorder—Lisinopril—systemic scleroderma	0.000524	0.0029	CcSEcCtD
Ezogabine—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000521	0.00289	CcSEcCtD
Ezogabine—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000521	0.00289	CcSEcCtD
Ezogabine—Muscle spasms—Leflunomide—systemic scleroderma	0.00052	0.00288	CcSEcCtD
Ezogabine—Mental disorder—Mycophenolic acid—systemic scleroderma	0.00052	0.00288	CcSEcCtD
Ezogabine—Malaise—Azathioprine—systemic scleroderma	0.000517	0.00286	CcSEcCtD
Ezogabine—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000516	0.00286	CcSEcCtD
Ezogabine—Leukopenia—Azathioprine—systemic scleroderma	0.000513	0.00284	CcSEcCtD
Ezogabine—Vision blurred—Leflunomide—systemic scleroderma	0.00051	0.00282	CcSEcCtD
Ezogabine—Asthenia—Pentoxifylline—systemic scleroderma	0.000507	0.00281	CcSEcCtD
Ezogabine—Ill-defined disorder—Leflunomide—systemic scleroderma	0.000502	0.00278	CcSEcCtD
Ezogabine—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.000497	0.00275	CcSEcCtD
Ezogabine—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.000496	0.00275	CcSEcCtD
Ezogabine—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000493	0.00273	CcSEcCtD
Ezogabine—Increased appetite—Prednisone—systemic scleroderma	0.000488	0.0027	CcSEcCtD
Ezogabine—Amnesia—Prednisone—systemic scleroderma	0.000488	0.0027	CcSEcCtD
Ezogabine—Malaise—Leflunomide—systemic scleroderma	0.000488	0.0027	CcSEcCtD
Ezogabine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000487	0.00269	CcSEcCtD
Ezogabine—Vertigo—Leflunomide—systemic scleroderma	0.000486	0.00269	CcSEcCtD
Ezogabine—Leukopenia—Leflunomide—systemic scleroderma	0.000484	0.00268	CcSEcCtD
Ezogabine—Tremor—Mycophenolic acid—systemic scleroderma	0.000484	0.00268	CcSEcCtD
Ezogabine—Coma—Methotrexate—systemic scleroderma	0.000482	0.00267	CcSEcCtD
Ezogabine—Discomfort—Azathioprine—systemic scleroderma	0.000482	0.00267	CcSEcCtD
Ezogabine—Paraesthesia—Captopril—systemic scleroderma	0.000481	0.00266	CcSEcCtD
Ezogabine—Ill-defined disorder—Mycophenolic acid—systemic scleroderma	0.000479	0.00265	CcSEcCtD
Ezogabine—Dyspnoea—Captopril—systemic scleroderma	0.000478	0.00264	CcSEcCtD
Ezogabine—Somnolence—Captopril—systemic scleroderma	0.000476	0.00264	CcSEcCtD
Ezogabine—Alopecia—Lisinopril—systemic scleroderma	0.000472	0.00261	CcSEcCtD
Ezogabine—Dyspepsia—Captopril—systemic scleroderma	0.000472	0.00261	CcSEcCtD
Ezogabine—Mental disorder—Lisinopril—systemic scleroderma	0.000468	0.00259	CcSEcCtD
Ezogabine—Dizziness—Pentoxifylline—systemic scleroderma	0.000468	0.00259	CcSEcCtD
Ezogabine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.000466	0.00258	CcSEcCtD
Ezogabine—Malaise—Mycophenolic acid—systemic scleroderma	0.000466	0.00258	CcSEcCtD
Ezogabine—Malnutrition—Lisinopril—systemic scleroderma	0.000465	0.00257	CcSEcCtD
Ezogabine—Infection—Azathioprine—systemic scleroderma	0.000465	0.00257	CcSEcCtD
Ezogabine—Vertigo—Mycophenolic acid—systemic scleroderma	0.000464	0.00257	CcSEcCtD
Ezogabine—Syncope—Mycophenolic acid—systemic scleroderma	0.000463	0.00256	CcSEcCtD
Ezogabine—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000462	0.00256	CcSEcCtD
Ezogabine—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000462	0.00256	CcSEcCtD
Ezogabine—Fatigue—Captopril—systemic scleroderma	0.000462	0.00256	CcSEcCtD
Ezogabine—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000461	0.00255	CcSEcCtD
Ezogabine—Anxiety—Leflunomide—systemic scleroderma	0.000459	0.00254	CcSEcCtD
Ezogabine—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00254	CcSEcCtD
Ezogabine—Osteoarthritis—Prednisone—systemic scleroderma	0.000459	0.00254	CcSEcCtD
Ezogabine—Constipation—Captopril—systemic scleroderma	0.000458	0.00254	CcSEcCtD
Ezogabine—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000458	0.00253	CcSEcCtD
Ezogabine—Discomfort—Leflunomide—systemic scleroderma	0.000455	0.00252	CcSEcCtD
Ezogabine—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000454	0.00251	CcSEcCtD
Ezogabine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000451	0.0025	CcSEcCtD
Ezogabine—Dry mouth—Leflunomide—systemic scleroderma	0.000451	0.00249	CcSEcCtD
Ezogabine—Psychotic disorder—Prednisone—systemic scleroderma	0.000448	0.00248	CcSEcCtD
Ezogabine—Muscle spasms—Lisinopril—systemic scleroderma	0.000447	0.00247	CcSEcCtD
Ezogabine—Rash—Pentoxifylline—systemic scleroderma	0.000446	0.00247	CcSEcCtD
Ezogabine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000445	0.00247	CcSEcCtD
Ezogabine—Feeling abnormal—Captopril—systemic scleroderma	0.000442	0.00244	CcSEcCtD
Ezogabine—Infection—Leflunomide—systemic scleroderma	0.000439	0.00243	CcSEcCtD
Ezogabine—Vision blurred—Lisinopril—systemic scleroderma	0.000438	0.00243	CcSEcCtD
Ezogabine—Anxiety—Mycophenolic acid—systemic scleroderma	0.000438	0.00242	CcSEcCtD
Ezogabine—Asthenia—Mometasone—systemic scleroderma	0.000438	0.00242	CcSEcCtD
Ezogabine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000437	0.00242	CcSEcCtD
Ezogabine—Tremor—Lisinopril—systemic scleroderma	0.000436	0.00241	CcSEcCtD
Ezogabine—Discomfort—Mycophenolic acid—systemic scleroderma	0.000434	0.0024	CcSEcCtD
Ezogabine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000433	0.0024	CcSEcCtD
Ezogabine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000432	0.00239	CcSEcCtD
Ezogabine—Ill-defined disorder—Lisinopril—systemic scleroderma	0.000431	0.00239	CcSEcCtD
Ezogabine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00043	0.00238	CcSEcCtD
Ezogabine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000427	0.00236	CcSEcCtD
Ezogabine—Confusional state—Mycophenolic acid—systemic scleroderma	0.000425	0.00235	CcSEcCtD
Ezogabine—Nausea—Pentoxifylline—systemic scleroderma	0.00042	0.00232	CcSEcCtD
Ezogabine—Malaise—Lisinopril—systemic scleroderma	0.000419	0.00232	CcSEcCtD
Ezogabine—Infection—Mycophenolic acid—systemic scleroderma	0.000419	0.00232	CcSEcCtD
Ezogabine—Vertigo—Lisinopril—systemic scleroderma	0.000418	0.00231	CcSEcCtD
Ezogabine—Syncope—Lisinopril—systemic scleroderma	0.000417	0.00231	CcSEcCtD
Ezogabine—Leukopenia—Lisinopril—systemic scleroderma	0.000416	0.0023	CcSEcCtD
Ezogabine—Shock—Mycophenolic acid—systemic scleroderma	0.000415	0.00229	CcSEcCtD
Ezogabine—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000414	0.00229	CcSEcCtD
Ezogabine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000413	0.00229	CcSEcCtD
Ezogabine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000413	0.00228	CcSEcCtD
Ezogabine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00041	0.00227	CcSEcCtD
Ezogabine—Loss of consciousness—Lisinopril—systemic scleroderma	0.000409	0.00226	CcSEcCtD
Ezogabine—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000407	0.00225	CcSEcCtD
Ezogabine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000407	0.00225	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000404	0.00223	CcSEcCtD
Ezogabine—Paraesthesia—Leflunomide—systemic scleroderma	0.000397	0.00219	CcSEcCtD
Ezogabine—Anxiety—Lisinopril—systemic scleroderma	0.000395	0.00218	CcSEcCtD
Ezogabine—Dyspnoea—Leflunomide—systemic scleroderma	0.000394	0.00218	CcSEcCtD
Ezogabine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000392	0.00217	CcSEcCtD
Ezogabine—Discomfort—Lisinopril—systemic scleroderma	0.000391	0.00216	CcSEcCtD
Ezogabine—Dyspepsia—Leflunomide—systemic scleroderma	0.000389	0.00215	CcSEcCtD
Ezogabine—Dry mouth—Lisinopril—systemic scleroderma	0.000387	0.00214	CcSEcCtD
Ezogabine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000385	0.00213	CcSEcCtD
Ezogabine—Rash—Mometasone—systemic scleroderma	0.000385	0.00213	CcSEcCtD
Ezogabine—Asthenia—Captopril—systemic scleroderma	0.000385	0.00213	CcSEcCtD
Ezogabine—Dermatitis—Mometasone—systemic scleroderma	0.000384	0.00213	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—systemic scleroderma	0.000383	0.00212	CcSEcCtD
Ezogabine—Confusional state—Lisinopril—systemic scleroderma	0.000383	0.00212	CcSEcCtD
Ezogabine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000382	0.00211	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000381	0.00211	CcSEcCtD
Ezogabine—Fatigue—Leflunomide—systemic scleroderma	0.000381	0.00211	CcSEcCtD
Ezogabine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000378	0.00209	CcSEcCtD
Ezogabine—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000378	0.00209	CcSEcCtD
Ezogabine—Constipation—Leflunomide—systemic scleroderma	0.000378	0.00209	CcSEcCtD
Ezogabine—Infection—Lisinopril—systemic scleroderma	0.000377	0.00209	CcSEcCtD
Ezogabine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000376	0.00208	CcSEcCtD
Ezogabine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000375	0.00207	CcSEcCtD
Ezogabine—Shock—Lisinopril—systemic scleroderma	0.000373	0.00207	CcSEcCtD
Ezogabine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000372	0.00206	CcSEcCtD
Ezogabine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000371	0.00205	CcSEcCtD
Ezogabine—Neutropenia—Prednisone—systemic scleroderma	0.000371	0.00205	CcSEcCtD
Ezogabine—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000367	0.00203	CcSEcCtD
Ezogabine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000367	0.00203	CcSEcCtD
Ezogabine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000366	0.00203	CcSEcCtD
Ezogabine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000365	0.00202	CcSEcCtD
Ezogabine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000365	0.00202	CcSEcCtD
Ezogabine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000364	0.00201	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000364	0.00201	CcSEcCtD
Ezogabine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000363	0.00201	CcSEcCtD
Ezogabine—Nausea—Mometasone—systemic scleroderma	0.000362	0.00201	CcSEcCtD
Ezogabine—Weight increased—Prednisone—systemic scleroderma	0.000361	0.002	CcSEcCtD
Ezogabine—Constipation—Mycophenolic acid—systemic scleroderma	0.00036	0.00199	CcSEcCtD
Ezogabine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000358	0.00198	CcSEcCtD
Ezogabine—Dizziness—Captopril—systemic scleroderma	0.000354	0.00196	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000354	0.00196	CcSEcCtD
Ezogabine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000347	0.00192	CcSEcCtD
Ezogabine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000346	0.00191	CcSEcCtD
Ezogabine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000343	0.0019	CcSEcCtD
Ezogabine—Paraesthesia—Lisinopril—systemic scleroderma	0.000341	0.00189	CcSEcCtD
Ezogabine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000339	0.00188	CcSEcCtD
Ezogabine—Dyspnoea—Lisinopril—systemic scleroderma	0.000338	0.00187	CcSEcCtD
Ezogabine—Rash—Captopril—systemic scleroderma	0.000338	0.00187	CcSEcCtD
Ezogabine—Dermatitis—Captopril—systemic scleroderma	0.000338	0.00187	CcSEcCtD
Ezogabine—Somnolence—Lisinopril—systemic scleroderma	0.000337	0.00187	CcSEcCtD
Ezogabine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000335	0.00186	CcSEcCtD
Ezogabine—Dyspepsia—Lisinopril—systemic scleroderma	0.000334	0.00185	CcSEcCtD
Ezogabine—Infection—Mycophenolate mofetil—systemic scleroderma	0.00033	0.00183	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000328	0.00181	CcSEcCtD
Ezogabine—Fatigue—Lisinopril—systemic scleroderma	0.000327	0.00181	CcSEcCtD
Ezogabine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000327	0.00181	CcSEcCtD
Ezogabine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000326	0.0018	CcSEcCtD
Ezogabine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000326	0.0018	CcSEcCtD
Ezogabine—Constipation—Lisinopril—systemic scleroderma	0.000325	0.0018	CcSEcCtD
Ezogabine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000321	0.00178	CcSEcCtD
Ezogabine—Nausea—Captopril—systemic scleroderma	0.000318	0.00176	CcSEcCtD
Ezogabine—Asthenia—Leflunomide—systemic scleroderma	0.000317	0.00175	CcSEcCtD
Ezogabine—Hallucination—Prednisone—systemic scleroderma	0.000316	0.00175	CcSEcCtD
Ezogabine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000313	0.00173	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—systemic scleroderma	0.00031	0.00171	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—systemic scleroderma	0.00031	0.00171	CcSEcCtD
Ezogabine—Dizziness—Azathioprine—systemic scleroderma	0.000309	0.00171	CcSEcCtD
Ezogabine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000302	0.00167	CcSEcCtD
Ezogabine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000299	0.00165	CcSEcCtD
Ezogabine—Eye disorder—Prednisone—systemic scleroderma	0.000296	0.00164	CcSEcCtD
Ezogabine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000296	0.00164	CcSEcCtD
Ezogabine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000296	0.00164	CcSEcCtD
Ezogabine—Infestation—Methotrexate—systemic scleroderma	0.000295	0.00163	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—systemic scleroderma	0.000295	0.00163	CcSEcCtD
Ezogabine—Rash—Azathioprine—systemic scleroderma	0.000295	0.00163	CcSEcCtD
Ezogabine—Dermatitis—Azathioprine—systemic scleroderma	0.000295	0.00163	CcSEcCtD
Ezogabine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000293	0.00162	CcSEcCtD
Ezogabine—Dizziness—Leflunomide—systemic scleroderma	0.000292	0.00162	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000287	0.00159	CcSEcCtD
Ezogabine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000284	0.00157	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—systemic scleroderma	0.000282	0.00156	CcSEcCtD
Ezogabine—Alopecia—Prednisone—systemic scleroderma	0.00028	0.00155	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000279	0.00155	CcSEcCtD
Ezogabine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000279	0.00154	CcSEcCtD
Ezogabine—Rash—Leflunomide—systemic scleroderma	0.000278	0.00154	CcSEcCtD
Ezogabine—Dermatitis—Leflunomide—systemic scleroderma	0.000278	0.00154	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—systemic scleroderma	0.000278	0.00154	CcSEcCtD
Ezogabine—Nausea—Azathioprine—systemic scleroderma	0.000278	0.00154	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—systemic scleroderma	0.000276	0.00153	CcSEcCtD
Ezogabine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000274	0.00152	CcSEcCtD
Ezogabine—Asthenia—Lisinopril—systemic scleroderma	0.000272	0.00151	CcSEcCtD
Ezogabine—Rash—Mycophenolic acid—systemic scleroderma	0.000266	0.00147	CcSEcCtD
Ezogabine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000265	0.00147	CcSEcCtD
Ezogabine—Nausea—Leflunomide—systemic scleroderma	0.000262	0.00145	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000262	0.00145	CcSEcCtD
Ezogabine—Vision blurred—Prednisone—systemic scleroderma	0.00026	0.00144	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—systemic scleroderma	0.00026	0.00144	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000256	0.00142	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—systemic scleroderma	0.000256	0.00141	CcSEcCtD
Ezogabine—Dizziness—Lisinopril—systemic scleroderma	0.000251	0.00139	CcSEcCtD
Ezogabine—Nausea—Mycophenolic acid—systemic scleroderma	0.00025	0.00139	CcSEcCtD
Ezogabine—Malaise—Prednisone—systemic scleroderma	0.000249	0.00138	CcSEcCtD
Ezogabine—Vertigo—Prednisone—systemic scleroderma	0.000248	0.00137	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—systemic scleroderma	0.000248	0.00137	CcSEcCtD
Ezogabine—Syncope—Prednisone—systemic scleroderma	0.000248	0.00137	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisone—systemic scleroderma	0.000243	0.00134	CcSEcCtD
Ezogabine—Rash—Lisinopril—systemic scleroderma	0.000239	0.00132	CcSEcCtD
Ezogabine—Dermatitis—Lisinopril—systemic scleroderma	0.000239	0.00132	CcSEcCtD
Ezogabine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00132	CcSEcCtD
Ezogabine—Anxiety—Prednisone—systemic scleroderma	0.000234	0.0013	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—systemic scleroderma	0.000234	0.0013	CcSEcCtD
Ezogabine—Discomfort—Prednisone—systemic scleroderma	0.000232	0.00129	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—systemic scleroderma	0.000232	0.00129	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—systemic scleroderma	0.000231	0.00128	CcSEcCtD
Ezogabine—Nausea—Lisinopril—systemic scleroderma	0.000225	0.00125	CcSEcCtD
Ezogabine—Infection—Prednisone—systemic scleroderma	0.000224	0.00124	CcSEcCtD
Ezogabine—Shock—Prednisone—systemic scleroderma	0.000222	0.00123	CcSEcCtD
Ezogabine—Nervous system disorder—Prednisone—systemic scleroderma	0.000221	0.00122	CcSEcCtD
Ezogabine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00022	0.00122	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000218	0.00121	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—systemic scleroderma	0.000218	0.0012	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000214	0.00119	CcSEcCtD
Ezogabine—Rash—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00116	CcSEcCtD
Ezogabine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000209	0.00116	CcSEcCtD
Ezogabine—Malaise—Methotrexate—systemic scleroderma	0.000208	0.00115	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—systemic scleroderma	0.000207	0.00115	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—systemic scleroderma	0.000207	0.00114	CcSEcCtD
Ezogabine—Paraesthesia—Prednisone—systemic scleroderma	0.000202	0.00112	CcSEcCtD
Ezogabine—Dyspepsia—Prednisone—systemic scleroderma	0.000198	0.0011	CcSEcCtD
Ezogabine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000198	0.00109	CcSEcCtD
Ezogabine—Fatigue—Prednisone—systemic scleroderma	0.000194	0.00108	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—systemic scleroderma	0.000194	0.00107	CcSEcCtD
Ezogabine—Constipation—Prednisone—systemic scleroderma	0.000193	0.00107	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—systemic scleroderma	0.00019	0.00105	CcSEcCtD
Ezogabine—Infection—Methotrexate—systemic scleroderma	0.000187	0.00104	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisone—systemic scleroderma	0.000186	0.00103	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000185	0.00102	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000184	0.00102	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000182	0.00101	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—systemic scleroderma	0.000169	0.000936	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—systemic scleroderma	0.000168	0.000929	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—systemic scleroderma	0.000167	0.000927	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—systemic scleroderma	0.000166	0.000918	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000163	0.0009	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—systemic scleroderma	0.000162	0.000899	CcSEcCtD
Ezogabine—Asthenia—Prednisone—systemic scleroderma	0.000162	0.000895	CcSEcCtD
Ezogabine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000155	0.000859	CcSEcCtD
Ezogabine—Dizziness—Prednisone—systemic scleroderma	0.000149	0.000825	CcSEcCtD
Ezogabine—Rash—Prednisone—systemic scleroderma	0.000142	0.000786	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—systemic scleroderma	0.000142	0.000786	CcSEcCtD
Ezogabine—Asthenia—Methotrexate—systemic scleroderma	0.000135	0.000748	CcSEcCtD
Ezogabine—Nausea—Prednisone—systemic scleroderma	0.000134	0.000741	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—systemic scleroderma	0.000125	0.000689	CcSEcCtD
Ezogabine—Rash—Methotrexate—systemic scleroderma	0.000119	0.000657	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—systemic scleroderma	0.000119	0.000657	CcSEcCtD
Ezogabine—Nausea—Methotrexate—systemic scleroderma	0.000112	0.000619	CcSEcCtD
